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ABSTRACT 
Low levels of full-length Survival Motor Neuron (SMN) protein cause the motor neuron 
disease Spinal Muscular Atrophy (SMA). Whilst motor neurons undoubtedly contribute 
directly to SMA pathogenesis, the role of muscle is less clear. We demonstrate significant 
disruption to the molecular composition of skeletal muscle in pre-symptomatic severe SMA 
mice, in the absence of any detectable degenerative changes in lower motor neurons and with 
a molecular profile distinct from that of denervated muscle. Functional cluster analysis of 
proteomics data and phospho-histone H2AX labelling of DNA damage revealed increased 
activity of cell death pathways in SMA muscle. Robust up-regulation of Vdac2 and down-
regulation of parvalbumin in severe SMA mice was confirmed in a milder SMA mouse 
model and in human patient muscle biopsies. Molecular pathology of skeletal muscle was 
ameliorated in mice treated with the FDA-approved histone deacetylase inhibitor, SAHA. We 
conclude that intrinsic pathology of skeletal muscle is an important and reversible event in 
SMA and also suggest that muscle proteins have the potential to act as novel biomarkers in 
SMA. 
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INTRODUCTION 
Proximal autosomal spinal muscular atrophy (SMA) is a predominantly childhood form of 
motor neuron disease and is the most common genetic cause of infant mortality, with an 
incidence of 1:6,000-10,000 and a carrier frequency of 1:35 [1,2]. SMA is caused by low 
expression levels of full-length survival motor neuron (SMN) protein, resulting from 
disruption of the survival motor neuron (SMN1) gene [3,4].  There are two nearly identical 
copies of this gene in humans; the telomeric SMN1 gene and the centromeric SMN2 gene. 
The SMN2 gene, however, produces only 10% of full length SMN protein due to a defective 
splicing pattern [4,5]. Retention of at least one copy of SMN2 in SMA patients therefore leads 
to low residual levels of SMN protein. Although SMN protein is ubiquitously expressed, the 
major pathological hallmarks of SMA are focussed on the neuromuscular system, including a 
loss of lower motor neurons from the ventral horn of the spinal cord and atrophy of skeletal 
muscle [6-9].  
 
Whilst most research to date has focussed on examining how low levels of SMN lead to 
pathological changes in motor neurons, the contribution of muscle to the pathogenesis of 
SMA remains unclear. Although pathological changes in SMA muscle, including evidence of 
increased levels of apoptosis, are a well-established hallmark of SMA [10-14], it has 
generally been assumed that changes in muscle occur simply as a secondary consequence of 
the degeneration of innervating lower motor neurons, rendering muscle fibres denervated. 
Studies have shown that restoring SMN protein levels in neurons can significantly ameliorate 
disease progression in SMA animal models [15,16]. However, these studies could not rule out 
an additional contribution resulting from restoration of SMN levels in muscle, raising the 
possibility that intrinsic responses to low levels of SMN in skeletal muscle may also 
contribute directly to SMA pathogenesis [15,17-24]. Moreover, SMN protein is present in 
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muscle sarcomeres from both mice and Drosophila, alongside other associated SMN complex 
proteins such as gemins [22,25].  Establishing whether skeletal muscle directly contributes to 
SMA pathogenesis therefore remains a critical question for understanding SMA pathogenesis 
as well as for the successful targeting of future therapeutic strategies. Previous attempts to 
address this question have been hampered, at least in part, by the fact that it has proven 
difficult to distinguish secondary pathological changes, induced as a consequence of 
denervation due to functional and structural deficits in lower motor neurons, from changes 
intrinsic to muscle. Moreover, studies of isolated muscle fibres from human SMA patients in 
vitro [20,24,26] are similarly defined by the fact that they are, as a direct result of the 
experimental protocol, devoid of lower motor neuron innervation and therefore denervated.  
 
Here, we have utilised a skeletal muscle preparation from an established mouse model of 
severe SMA (Smn-/-;SMN2+/+) [27] where it is possible to examine molecular changes 
occurring in skeletal muscle in vivo, in the absence of any detectable denervation-inducing 
changes in corresponding lower motor neurons. We used this preparation to reveal 
modifications in the molecular composition of skeletal muscle in SMA mice at a pre-
symptomatic age, with a molecular profile distinct from that of denervated muscle. Our 
findings were confirmed in a milder mouse model of SMA and also in muscle biopsies from 
human SMA patients. Finally, we demonstrate molecular pathology of skeletal muscle in 
SMA mice can be ameliorated by treatment with the FDA-approved histone deacetylase 
inhibitor, SAHA. 
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RESULTS  
The rostral band of levator auris longus allows examination of intrinsic changes to skeletal 
muscle in SMA  
In order to isolate and identify molecular changes occurring specifically in skeletal muscle 
during SMA, it is necessary to have an experimental system where low levels of SMN protein 
are present in muscle, but denervation due to degeneration of innervating lower motor 
neurons is absent. The homogeneous fast-twitch levator auris longus (LAL) muscle has two 
distinct bands (rostral and caudal) [28]. Motor neurons innervating the caudal band in the 
Smn-/-;SMN2 mouse model of severe SMA [27] are susceptible to SMA pathology (even at 
late-symptomatic stages), whereas those innervating the rostral band are resistant (see Fig 
1A) [28-30]. Importantly, our group and others have previously demonstrated that motor 
neurons innervating the rostral LAL develop normally in the pre-symptomatic period [30], 
with genetic and electrophysiological studies similarly indicating an absence of lower motor 
neuron pathology or neuromuscular junction dysfunction in the rostral LAL from early-
symptomatic SMA mice [31,32]. 
 
We validated the absence of any degenerative pathology in lower motor neurons innervating 
the rostral LAL in Smn-/-;SMN2 mice at a pre-symptomatic age (postnatal day 1; P1; Fig 1B): 
>98% of neuromuscular junctions were fully innervated by intact motor axon collaterals in 
both Smn-/-;SMN2 mice and littermate controls and there was no evidence of abnormal 
neurofilament accumulations in motor nerve terminals in any of the muscles examined (N>5 
mice per genotype). Similarly, we found no evidence for denervation-induced muscle fibre 
shrinkage in the rostral LAL from Smn-/-;SMN2 mice at P1 (Fig 1C). Taken together with the 
previously published studies, we concluded that the rostral LAL at P1 represents a muscle 
preparation from an SMA mouse where no detectable neuronal degeneration or muscle 
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denervation is present, making it ideal for intrinsic molecular studies of muscle in SMA. As 
expected, however, there was still a 70-80% reduction in expression levels of SMN protein in 
the rostral LAL from Smn-/-;SMN2 mice at P1 compared with control littermates (Fig 1D).  
 
Label-free proteomics analysis of rostral LAL reveals molecular alterations to skeletal 
muscle in pre-symptomatic Smn-/-;SMN2 mice 
Label-free proteomics techniques were used to quantify and compare the molecular 
composition of the rostral LAL from P1 Smn-/-;SMN2 mice compared to littermate controls 
(Smn+/+;SMN2; N=9 mice per genotype; see methods). Direct comparison of rostral LAL 
proteomes revealed that 65 out of the 345 identified individual proteins (19%) were up-
regulated >20% in Smn-/-;SMN2 mice (Table I & Supplementary Table I). Of these, 20 
proteins showed a greater than 2-fold increase in expression levels. In addition, 32 out of the 
345 identified proteins (9%) were down-regulated >20% in Smn-/-;SMN2 mice (Table II & 
Supplementary Table II). The increased expression profiles of many proteins in Smn-/-;SMN2 
tissue confirmed that the changes observed were active responses to low levels of SMN in 
muscle, and were not simply occurring as a result of a global decrease in protein synthesis. 
We initially validated the proteomics data by quantifying expression levels of one 
significantly downregulated protein (parvalbumin) in immunohistochemically labelled 
muscle preparations (Supplementary Fig 1).   
 
To identify any functional clustering of proteins found to have modified expression levels in 
the rostral LAL of SMA mice, we performed a systems level analysis of the proteomics data 
using Ingenuity Pathway Analysis software. 83 out of the 97 proteins identified were listed in 
this software and therefore available for data mining of the existing published literature to 
determine potential functional clustering. This analysis revealed that many of the proteins 
 by guest on June 20, 2013
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
7 
with modified expression profiles in muscle from Smn-/-;SMN2 mice are reported to regulate 
muscle function and pathology (Table III). For example, the functional cluster most 
significantly changed in SMA muscle contained proteins known to contribute to skeletal and 
muscular disorders: 44 of the proteins changed in Smn-/-;SMN2 muscle (53% of the total list) 
have links to these disorders, 6 of which also directly contribute to myopathies (Table III). 
Similarly, modifications were observed in clusters of proteins contributing to cell death 
pathways and morphological development (Table III). A different analysis at the systems 
level also highlighted disruption of two protein interaction networks (identified by known 
direct or indirect interactions between individual proteins) implicated in development and 
function of the skeletal and muscular systems (Supplementary Fig 2).  
 
Evidenced for increased cell death in SMA muscle  
The finding that 35% of the proteins submitted for functional clustering analysis contribute to 
cell death pathways (Table III) was of particular interest given that apoptotic cell death has 
previously been reported in SMA muscle [10-14]. Indeed, several of the protein expression 
changes identified in the rostral LAL of SMA mice have previously been implicated in 
activation of apoptotic and non-apoptotic cell death pathways (e.g. Vdac2) [33,34]. We 
therefore asked whether markers of cell death were increased in the rostral LAL of Smn-/-
;SMN2 mice. Immunohistochemical labelling for phospho-histone H2AX (H2AX) was used 
as a sensitive marker of DNA damage during the early stages of apoptosis [35,36]. Cells 
strongly expressing H2AX were rarely observed in rostral LAL from littermate control mice, 
but were readily identifiable in Smn-/-;SMN2 mice (Fig 2), suggesting a significant elevation 
in levels of cell death in the SMA mice. Thus, at least some of the protein expression changes 
identified in the rostral LAL of SMA mice (e.g. cell death proteins; see Table III) were 
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contributing directly to biological pathways regulating muscle responses to low SMN levels 
in vivo. 
 
Changes in the molecular composition of skeletal muscle in SMA mice are distinct from those 
elicited following acute or chronic denervation 
To confirm that the molecular changes observed in SMA muscle were not occurring as a 
result of acute or chronic denervation subsequent to motor neuron pathology, we compared 
our proteomics data to similar data from proteomics studies of chronically denervated muscle 
(>1 week following nerve injury; Fig 3A). The profile of expression changes observed in 
rostral LAL from SMA mice was clearly distinct from those modified following denervation 
(Fig 3A) [37-39]. As these previous studies were all performed on chronically denervated 
muscle, we also quantified expression levels of two proteins significantly altered in SMA 
muscle (Vdac2 and parvalbumin) in acutely denervated muscles. We lesioned the sciatic 
nerve in wild-type mice and isolated the denervated flexor digitorum brevis (FDB) and deep 
lumbrical muscles from the hind-foot 24 hours later. As expected, morphological evaluation 
of neuromuscular junctions confirmed complete denervation in all muscles examined (data 
not shown). However, levels of both Vdac2 and parvalbumin remained unchanged (Fig 3B).  
 
Molecular pathology of muscle is also present in human SMA patients 
We next examined whether molecular changes observed in pre-symptomatic SMA mice were 
also present in skeletal muscle from human SMA patients. Quantitative fluorescent western 
blotting was performed on human SMA patient Quadriceps femoris muscle biopsy samples, 
to establish expression levels of Vdac2 and parvalbumin (Fig 4). Biopsies were obtained from 
type II/III SMA patients (aged between 3 and 25 years old; see methods), with genetic 
diagnosis of SMA confirmed by a homozygous deletion of the SMN1 gene. Three age-
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matched control samples, genetically confirmed to have no mutations in the SMN1 gene, 
were used for comparison. As expected, SMN protein expression levels were significantly 
decreased in SMA patient samples compared to control samples (Fig 4A/B). Quantitative 
western blotting revealed that both Vdac2 and parvalbumin showed similar alterations in 
expression levels to those previously observed in Smn-/-;SMN2 mice: Vdac2 was significantly 
up-regulated >3 fold in SMA patient muscle (Fig 4C) and parvalbumin was significantly 
down-regulated >4 fold (Fig 4D).  
 
Molecular pathology of skeletal muscle is reversed by treatment with the FDA-approved 
histone deacetylase inhibitor, SAHA  
The finding that levels of full-length SMN protein produced by the SMN2 gene can be 
modulated by small molecules and drugs has raised the possibility of a therapy for SMA. For 
example, epigenetic modulation using histone deacetylase inhibitors (HDACi) appears to be 
successful [40], with the HDACi SAHA (also known as Vorinostat or Zolinza) elevating full-
length SMN protein levels in SMA mouse models in vivo, resulting in a 30% increase in 
mean survival and amelioration of muscle fibre size shrinkage [41]. To examine whether 
HDAC inhibitors are capable of directly targeting molecular changes in muscle during SMA, 
we examined expression levels of Vdac2, parvalbumin and the cell death marker H2AX in 
skeletal muscle from SMA mice treated with SAHA.  
 
For these experiments we used a milder SMA mouse model (Taiwanese-SMA mice) with a 
new breeding protocol (Smn-/-;SMN2tg/tg x Smn-/+) [41] to generate affected SMA mice that 
survive ~10 days postnatal on a congenic FVB/N genetic background. The slightly longer 
life-span of this model is better for testing potential therapeutic agents than the more severe 
Smn-/-;SMN2 model [41]. We first confirmed that molecular pathological changes similar to 
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those observed in Smn-/-;SMN2 mice were also present in untreated late-symptomatic (P10) 
Taiwanese-SMA mice. As expected, SMN protein levels in the gastrocnemius muscle were 
reduced to around 25% of those in littermate controls (Fig 5A/B). Vdac2 levels were 
increased (Fig 5C) and parvalbumin levels were decreased (Fig 5D) in Taiwanese-SMA 
mice, and increased cell death was confirmed by an increase in levels of H2AX (Fig 5E). 
Importantly, it has previously been demonstrated that neuronal pathology is present in the 
gastrocnemius muscle of Taiwanese-SMA mice at P10 (including denervation of muscle 
fibres) [41]. Thus, the molecular changes initially observed in the LAL muscle of severe 
SMA mice at P1 in the absence of neuronal pathology were also present in anatomically 
distinct muscles susceptible to denervation in SMA. 
 
Taiwanese-SMA mice and littermate controls were treated with SAHA from birth via oral 
administration of 25mg/kg SAHA (dissolved in DMSO) twice daily [41]. For control 
experiments, mice were dosed with DMSO alone. As previously reported [41], SAHA 
treatment significantly increased SMN protein expression levels in the gastrocnemius muscle 
(Fig 5). Importantly, however, SAHA treatment significantly ameliorated SMN-induced 
changes in levels of Vdac2, parvalbumin and H2AX (Fig 5).  
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DISCUSSION 
In this study we have identified and characterised molecular pathology of skeletal muscle in 
an established mouse model of severe SMA. These changes were present during the earliest 
stages of disease and occured in the absence of any detectable degeneration of lower motor 
neurons. The molecular profile of muscle pathology in SMA was distinct from that of 
denervated muscle, with functional cluster analysis of proteomics data and H2AX labelling 
highlighting increased activity of cell death pathways. We confirmed the robust up-regulation 
of Vdac2 and down-regulation of parvalbumin in a different (milder) SMA mouse model and 
also in human patient muscle biopsies. Molecular pathology of skeletal muscle was 
ameliorated in mice treated with the FDA-approved HDACi SAHA.  
 
This study provides significant in vivo experimental data from mouse models and human 
patient material to support the hypothesis that SMA-induced changes in muscle cannot solely 
be attributed to motor neuron degeneration. For example, the molecular changes we identified 
in SMA muscle were distinct from those reported in chronically or acutely denervated 
muscle. The proposal that muscle changes can occur in the absence of neuronal pathology in 
SMA is supported by several previous studies. For example, studies of SMN protein 
expression and localisation have identified the SMN complex in muscle from both mice and 
Drosophila, as well as in C2C12 cells in vitro [21,22,25]. Moreover, in vitro studies have 
shown that muscle cells derived from SMA patients can inhibit neuronal outgrowth and 
development when co-cultured with wild-type healthy motor neurons [12,17,42] and a recent 
study of myotubes from human SMA fetuses also revealed a delay in growth and maturation 
in vitro [24]. Moreover, fibroblast growth factor (FGF) signalling in muscle can ameliorate 
SMN-associated abnormalities at the neuromuscular junction in Drosophila [43] and 
increased levels of insulin-like growth factor (IGF-1) in muscle modulates SMA phenotype in 
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mice [44]. Taken together, these findings suggest SMN levels are critical for the 
establishment and maintenance of molecular homeostasis in skeletal muscle. Thus, direct 
disruption of muscle resulting from low levels of SMN is likely to be a significant contributor 
to SMA pathogenesis, alongside pathological changes in motor neurons. 
 
Interestingly, many of the proteins shown to have altered expression profiles in skeletal 
muscle during SMA have previously been implicated in other neuromuscular diseases where 
intrinsic muscle pathology occurs. For example, decorin is associated with modified 
proliferation and differentiation of myogenic cells in x-linked muscular dystrophy [45] and 
reticulocalbin 1 expression is altered in dystrophic muscles [46].  Galectin 1 has been 
implicated in myoblast differentiation, skeletal muscle development and muscle regeneration 
[47,48]. Similarly, proteins such as serpin H1 (a.k.a. HSP47) and vinculin, through its 
interaction with dysferlin, have been implicated in muscle fibre repair and maintenance of the 
muscle membrane respectively [49,50]. Thus, the proteins we identified as have altered 
expression profiles in SMA muscle are consistent with those that might be expected to 
regulate intrinsic muscular pathology based on findings from other neuromuscular disorders. 
 
Two proteins of particular interest in the context of this study are Vdac2 and parvalbumin. 
Both showed modified expression levels in skeletal muscle across two different mouse 
models of SMA as well as in human patients, and both responded significantly to SAHA 
treatment. This raises the possibility of their use as novel biomarkers to report directly on the 
pathological status of the neuromuscular system in human patients. Such biomarkers are 
urgently required for clinical trials in SMA patient cohorts, where appropriate molecular 
biomarkers are currently lacking. The observation that the expression profiles of these two 
proteins are changed in opposing directions in SMA further strengthens their potential utility 
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as biomarkers, providing an internal control against any global up- or down-regulation of 
protein expression in individual patients. Vdac2 is a mitochondrial protein associated with 
formation of channels in the mitochondrial outer membrane, responsible for regulating cell 
death pathways and calcium signalling [51-53]. It is also a core component of the muscle 
response to aging [54] and has been implicated in early pathogenic events occurring in the 
mdx mouse model of muscular dystrophy [55]. Parvalbumin is a cytosolic calcium buffer in 
muscle, breakdown of which similarly contributes to muscular dystrophy [56,57]. 
 
Finally, our finding that the altered molecular composition of skeletal muscle in SMA is 
reversible using the HDACi SAHA highlights the potential to treat SMN-induced muscle 
changes using small molecules and drugs. SAHA has been shown to penetrate into a range of 
tissues following administration - including the nervous system and muscle [41,58,59] - and 
is approved for use in humans by the FDA in the US. SAHA is a second generation HDACi, 
so it is likely that future generations will have even higher specificity and potency, increasing 
their attractiveness for use in SMA patients. Our findings suggest that attempts to develop 
better HDACi that specifically target SMN levels in skeletal muscle would likely lead to 
effective therapeutic options for SMA. Testing other currently available HDACi for the 
potential to rescue muscle pathology in vivo will also be an important next step.  The current 
data do not allow us to ascertain whether raised SMN levels in muscle induced by SAHA also 
have a secondary impact on pathological changes occurring in other cell types (e.g. motor 
neurons), due to systemic delivery of the HDACi [41]. Thus, the potential for a causal 
relationship between the rescue of pathological changes occurring in muscle in SAHA treated 
SMA mice and the reduction in pathology of motor neurons previously reported [41] remains 
untested and warrants further investigation. Nevertheless, the current study shows that 
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intrinsic pathological changes in muscle are a significant feature of SMA, regardless of their 
possible secondary impact on other cell types. 
 
MATERIALS AND METHODS 
Mice 
Smn+/-;SMN2 mice (Jackson labs strain no. 005024) were maintained as heterozygote 
breeding pairs under standard SPF conditions in animal care facilities in Edinburgh. Litters 
produced from SMA colonies were retrospectively genotyped using standard PCR protocols 
(JAX Mice Resources), as previously described [29]. Taiwanese-SMA mice were bred and 
maintained in micro-isolation chambers in Cologne as previously reported [41]. For SAHA 
experiments, litters of Taiwanese-SMA mice (containing SMA mice and littermate controls) 
were dosed twice daily from birth with either 25mg/kg SAHA dissolved in DMSO, or an 
equivalent volume of DMSO alone, via oral application with a feeding needle. All animal 
procedures and breeding were performed in accordance with Home Office guidelines in the 
UK and according to guidelines established by the Landesamt fur Natur, Umwelt und 
Verbraucherschutz NRW in Germany. 
 
Human Muscle Samples 
Quadriceps femoris biopsy samples were obtained from Fondazione IRCCS Istituto 
Neurologico “C. Besta” in Milan, Italy and Fondazione Ospedale Maggiore Polclinico 
Mangiagalli en Regina Elena, IRCCS in Milan, Italy through EuroBioBank 
(http://www.eurobiobank.org/). 
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Acute Nerve Degeneration  
Young adult wild-type (C57Bl/6J) mice (n=4) were anaesthetized by inhalation of isofluorane 
(2%, 1:1 N2O/O2) before exposing the sciatic nerve in the thigh and removing 1mm section of 
the nerve to ensure complete transection. Post-operative mice were kept in standard animal 
house conditions for 24 hours before sacrifice.  
Muscle Preparation 
Mouse: neonatal Smn-/-;SMN2 and wild-type (Smn+/+;SMN2) littermates were sacrificed by 
chilling on ice and decapitation. Levator auris longus (LAL, from the back of the neck) [28] 
muscles were dissected in oxygenated mammalian physiological saline. For proteomics and 
quantitative western blotting experiments, LAL muscles were separated into rostral and 
caudal bands and quickly frozen on dry ice. The muscles were stored in -80oC freezers until 
enough tissue was collected for analysis. C56Bl6/J mice subjected to sciatic nerve lesion 
were sacrificed and the flexor digitorum brevis (FDB) and deep lumbrical muscles were 
isolated. Muscle were either processed for immunohistochemistry or rapidly frozen on dry ice 
for subsequent western blotting. Neonatal Taiwanese-SMA mice and littermate controls were 
sacrificed and the gastrocnemius muscles dissected and immediately flash-frozen before 
storing at -80oC before being shipped to Edinburgh for analysis.  
 
Human: human tissues in the form of muscle biopsies were obtained from two different 
biobanks. Proteins from muscle biopsies were extracted in RIPA buffer with 10% protease 
inhibitor cocktail (Sigma) for quantitative western blotting. 
 
Label-free proteomics 
Protein was extracted in MEBC Buffer (50 mM TRIS, 100 mM NaCl, 5 mM NaEDTA, 5 
mM NaEGTA, 40 mM -glycerophosphate, 100 mM sodium fluoride (NaF), 100 mM 
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sodium orthovanadate, 0.25% NP-40, 1 Roche ‘complete’ protease inhibitor tablet, pH 7.4). 
Protein concentration was determined by BCA assay according to manufacturers instructions 
on solubilised muscle (WT-Rostral and KO-Rostral). Then 10ug aliquots of each muscle type 
were reduced with 10 mM DTT and alkylated with 50 mM iodoacetamide prior to digestion 
with trypsin (Roche, sequencing grade) overnight at 30oC. Technical replicates (3 x 2.5 ug) 
of each digested muscle type were injected onto a nLC-MS/MS system (Ultimate 3000 
(Dionex) coupled to a LTQ Orbitrap XL (Thermo Scientific). The peptides from each digest 
were separated over a 65 min linear gradient from 5-35% acetonitrile in 0.1% formic acid. 
The LTQ Orbitrap XL was configured with a TOP 5 methodology comprising a 60K 
resolution FT-MS full scan followed by IT-MS/MS scans for the 5 most intense peptide ions. 
The raw data was then imported into Progenesis LCMS for label free differential analysis and 
subsequent identification and quantitation of relative ion abundance ratios, both up-regulated 
and down-regulated. Individual peptide sequences generated by the proteomics analysis were 
submitted to MASCOT for protein identification. A stringent selection criteria was used 
before a protein was included; identification of at least two peptides was needed, a minimum 
cut-off of 20% change against the littermate controls was used and a p value of <0.05 [60,61]. 
 
Quantitative fluorescent western blotting 
Protein was extracted from both human and mouse muscle samples. Quantitative western 
blots were performed as described previously [60,62], using primary antibodies against SMN 
(BD Transduction laboratories or Santa Cruz), VDAC-2 (Abcam), Parvalbumin (Abcam), 
phospho-histone H2AX (Upstate) and beta-V-Tubulin (Abcam). Odyssey secondary 
antibodies were added according to manufacturers instructions (Goat anti rabbit IRDye 680 
or 800 and Goat anti mouse IRDye 680 or 800 dependant on required combinations). Blots 
were imaged using an Odyssey Infrared Imaging System (Li-COR, Biosciences) at 169µm 
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resolution. Where possible, each sample was independently run and measured multiple times 
to minimise user variability. 
 
In silico protein network and functional pathway analysis 
To obtain further insights into functional pathways modified as a result of low SMN levels in 
muscle, the Ingenuity Pathways Analysis (IPA) application (Ingenuity Systems) was used to 
analyse our proteomics data. IPA dynamically generates network of gene, protein, small 
molecule, drug, and disease associations on the basis of “hand-curated” data held in a 
proprietary database. Of the submitted protein candidate list (97 proteins in total), 83 proteins 
were recognized by the software and therefore eligible for pathway analysis. 
 
NMJ Immunohistochemistry and Muscle Fibre Diameter Measurements  
LALs from Smn-/-;SMN2 and littermate controls (P1 or P5) or FDB and deep lumbrical 
muscles from C56Bl6/J mice were fixed in 0.1M PBS containing 4% paraformaldehyde 
(Electron Microscopy Services) for 10 min and then exposed to -BTX conjugated to 
tetramethyl-rhodamin isothiocyanate (TRITC--BTX; 5mg/ml, Molecular Probes) to label 
post-synaptic acetylcholine receptors. Muscles were then processed for 
immunohistochemistry as previously described [29]. Primary antibodies against either 
neurofilament (2H3, Developmental Studies Hybridoma Bank) or phospho-histone H2AX 
(Upstate) were used. Before mounting in mowoil, the dissections were incubated in TOPRO3 
(Molecular probes) for 10 min. Fluorescence images were captured using a laser scanning 
confocal microscope (40x objective; ZEISS LSM 510) with 488nm, 543nm and 633 nm laser 
lines used for excitation. Confocal Z-series were merged using Zeiss software. 
Reconstructions of FITC-labelled muscle preparations were produced using Adobe 
Photoshop software by layering and combining multiple micrographs covering the entire 
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muscle. All images were prepared for publication using Adobe Photoshop. For muscle fibre 
diameter measurements, individual muscle fibre diameters were imaged using phase contrast 
optics on an inverted microscope equipped with a chilled CCD camera (20x/0.40 objective; 
Olympus IX71 microscope; Hammamatsu C4742-96-12G04) and measurements were made 
using ImageJ.  
 
Statistical analysis 
All data were collected into Microsoft Excel spreadsheets and then analysed using GraphPad 
Prism software. For all statistical analyses, P<0.05 was considered to be significant. 
Individual statistical tests used are detailed in the results section or figure legends. 
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LEGENDS TO FIGURES  
 
Figure 1. The rostral band of the LAL in pre-symptomatic SMA mice provides an 
experimental model to study SMN-induced changes in the molecular composition of 
muscle in the absence of neuronal pathology. (A) The middle panel shows a low-
magnification overview of the entire muscle innervation pattern of the levator auris longus 
(LAL) muscle from a SMA mouse (Smn-/-;SMN2) [29]. The red line indicates the 
demarcation point between the rostral band of the muscle (to the right) and the caudal band 
(to the left). The left panel shows an example of a high-power confocal micrograph of 
neuromuscular junctions in the caudal band of the muscle at post-natal day 5 (green; 
immunohistochemically labelled 150kDa neurofilament and SV2 synaptic vesicle proteins to 
highlight the motor neuron / red; acetylcholine receptors on skeletal muscle fibres labelled 
with TRITC-conjugated alpha-bungarotoxin). Note the presence of widespread neuronal 
pathology evidenced by the loss of neuronal inputs to motor endplates and presence of 
neurofilament accumulations [29]. The right panel shows an example of a high-power 
confocal micrograph of neuromuscular junctions in the rostral band of the muscle at post-
natal day 5. Note the preservation of motor neuron inputs, even at this late-symptomatic age. 
(B) A representative confocal micrograph showing immunohistochemically labelled 
neuromuscular junctions from the rostral band of the LAL from a SMA mouse at P1. Note 
the complete absence of any overt neuronal pathology (e.g. vacant endplates or neurofilament 
accumulations). (C) Bar chart (mean  S.E.M.) showing muscle fibre diameter in the rostral 
band of the LAL from both SMA mice (Smn-/-;SMN2) and littermate controls (Smn+/+;SMN2) 
at P1. There was no denervation induced muscle fibre atrophy in the SMA mice (P>0.05; 
unpaired, two-tailed t test; N>3 mice per genotype). (D) Representative western blot showing 
reduced expression levels of SMN protein in the rostral band of the LAL from SMA mice 
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compared to littermate controls. Beta-V-Tubulin was used as a loading control. Scale bars = 
20µm. 
Figure 2. Increased levels of cell death in the rostral LAL from SMA mice. (A/B) 
Representative fluorescence micrographs of rostral LAL muscle preparations from an Smn-/-
;SMN2 mouse (B) and a littermate control (A) immunohistochemically labelled for the cell 
death marker H2AX (green). Nuclei were labelled with TOPRO-3 (red). Almost all muscle 
nuclei in muscles from littermate control mice showed no, or weak, labelling (A), whereas 
strong H2Ax labelling was easily identified in SMA muscles (B). Images in panels A and B 
were taken with identical settings on the confocal microscope (e.g. laser intensity, gain, 
zoom, z-stack depth etc). (C) Bar chart (mean±s.e.m) showing a significant increase in the 
numbers of cells with intense H2AX labelling in the rostral LAL of Smn-/-;SMN2 mice 
(SMA) compared to littermate controls (Control) (P<0.05, Unpaired two-tailed t-test, N=3 
muscles). Scale bar = 10µm. 
Figure 3. Molecular pathology of SMA skeletal muscle is molecularly distinct from 
changes elicited following chronic or acute denervation. (A) Comparison of expression 
profiles of individual proteins identified in SMA muscle with expression changes observed in 
chronically denervated rodent muscle. Note that the molecular profile of SMA muscle was 
distinct from that in denervated muscle. NC = no change, NR = not reported, UP = increased 
expression, DOWN = decreased expression. (B) Bar chart (mean±s.e.m) showing expression 
levels of Vdac2 and parvalbumin in mouse flexor digitorum brevis muscles before (control) 
or 24 hours after (denervated) tibial nerve lesion. Neither protein showed a significant change 
in expression in denervated muscle (P>0.05; unpaired, two-tailed t test; N>3 mice per 
genotype). 
Figure 4. Molecular modifications are also present in skeletal muscle from human SMA 
patients. (A) Representative fluorescent western blots on quadriceps femoris biopsy samples 
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from SMA patients (type II or type III; aged between 3 and 25 years old) and non-SMA 
controls showing levels of SMN protein, beta-V-tubulin (loading control), Vdac2 and 
parvalbumin. (B-D) Bar charts showing expression levels of SMN, Vdac2 and parvalbumin 
in human SMA patient muscle compared to controls. Data is shown for individual patients 
(black and white bars to the left of the hashed line) as well as mean±s.e.m for each genotype 
(right of the line). SMN levels were significantly decreased in SMA patients (*P<0.05; 
unpaired, two-tailed t test; panel B), Vdac2 levels were significantly increased (*P<0.05; 
unpaired, two-tailed t test; panel C) and parvalbumin levels were significantly decreased 
(*P<0.05; panel B). 
Figure 5. Reversal of SMA-induced molecular pathology of skeletal muscle by treatment 
with SAHA. (A) Representative fluorescent western blots on gastrocnemius muscles from 
Taiwanese-SMA mice (SMA), littermate controls (Control) and SAHA-treated Taiwanese-
SMA mice (SMA+SAHA) at P10 showing levels of SMN protein, beta-V-tubulin (loading 
control), Vdac2, parvalbumin and H2AX. (B-E) Bar charts (mean±s.e.m) showing expression 
levels of SMN, Vdac2, parvalbumin and H2AX. SMN levels were significantly decreased in 
Taiwanese-SMA mice compared to controls (***P<0.001; ANOVA with Tukey’s post hoc 
test; panel B) and were significantly increased in SMA mice treated with SAHA (*P<0.05; 
panel B). Vdac2 levels were significantly increased in SMA mice (*P<0.05; panel C) and 
decreased by SAHA treatment (**P<0.01; panel C), returning to levels observed in littermate 
controls. Parvalbumin levels were significantly decreased in SMA mice (***P<0.001; panel 
D) but were increased by SAHA treatment (**P<0.01; panel D), restoring them to ~75% of 
those found in healthy control muscle. H2AX levels were significantly increased in SMA 
mice (***P<0.001; panel E) but were decreased by SAHA treatment (***P<0.001; panel E), 
restoring them to those found in healthy control muscle. n=19 independent measurements 
from N=5 mice (Control), n=17, N=5 (SMA), n=11, N=4 (SMA+SAHA). 
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Fig. 1 
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Fig. 3 
 
 
 
 
Fig. 4 
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Fig. 5 
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ABBREVIATIONS 
FDB – Flexor digitorum brevis 
HDACi – Histone deacetylase inhibitor 
LAL – Levator auris longus 
SAHA - Suberoylanilide hydroxamic acid 
SMA – Spinal muscular atrophy 
SMN – Survival motor neuron 
VDAC2 - Voltage-dependent anion-selective channel protein 2 
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